A form of gene therapy has shown significant benefit in men with a severe form of the bleeding disorder hemophilia A. "If approved, this first-generation gene therapy would offer a new choice for care ...

New study findings demonstrate that valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, significantly reduces bleeding episodes and dependency on factor VIII infusions over a 3-year ...

Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec conferred sustained bleeding control at 2 years among a cohort of men with severe ...

Hemophilia A is characterized by FVIII deficiency, leading to joint bleeds and chronic pain despite prophylactic therapy. Treatment options vary in sustaining FVIII levels, with gene therapy and ...

Hemophilia A is a rare, inherited condition that prevents your blood from clotting the way it should. People with hemophilia A do not make enough of a protein called factor VIII, which normally works ...

Humate-P is a specialized medication known as a “complex” because it contains two essential proteins your body needs to form clots: antihemophilic factor (factor VIII) and von Willebrand factor (VWF).